This study was terminated in the United States. It is testing rapastinel for depression.
Depression, SuicidalityDrugFrom 18 Years to 65 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether Rapastinel may be useful for adults experiencing depression.
What would participation involve?
Participants may receive Rapastinel, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in the United States.
Who is it mainly for?
This study appears to be mainly for adults with depression.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: December 15, 2017
Recruitment status
Terminated
Enrollment listed in the registry
138
Sponsor
Naurex, Inc, an affiliate of Allergan plc
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT03352453
Official title
A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients With Major Depressive Disorder
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
United States · 17 sites
The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham
Birmingham, Alabama
Site status: Not listed — confirm with the team
Collaborative NeuroScience Network, LLC
Garden Grove, California
Site status: Not listed — confirm with the team
Behavioral Research Specialists, LLC
Glendale, California
Site status: Not listed — confirm with the team
Asclepes Research Centers
Panorama City, California
Site status: Not listed — confirm with the team
Institute of Living
Hartford, Connecticut
Site status: Not listed — confirm with the team
Innovative Clinical Research, Inc
Hialeah, Florida
Site status: Not listed — confirm with the team
Research Centers of America, LLC
Oakland Park, Florida
Site status: Not listed — confirm with the team
Atlanta Center for Medical Research (ACMR)
Atlanta, Georgia
Site status: Not listed — confirm with the team
Alexian Brothers Center for Psychiatric Research
Hoffman Estates, Illinois
Site status: Not listed — confirm with the team
Lake Charles Clinical Trials
Lake Charles, Louisiana
Site status: Not listed — confirm with the team
CBH Health
Gaithersburg, Maryland
Site status: Not listed — confirm with the team
Altea Research Institute
Las Vegas, Nevada
Site status: Not listed — confirm with the team
Icahn School of Medicine at Mount Sinai
New York, New York
Site status: Not listed — confirm with the team
Cincinnati VA Medical Center
Cincinnati, Ohio
Site status: Not listed — confirm with the team
Pillar Clinical Research, LLC
Richardson, Texas
Site status: Not listed — confirm with the team
Carilion Medical Center, a Virginia Nonprofit Corporation
Roanoke, Virginia
Site status: Not listed — confirm with the team
Department of Veterans Affairs Salem VA Medical Center
Salem, Virginia
Site status: Not listed — confirm with the team
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT03352453. We help you review the study, but cannot decide medical eligibility.
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Rapastinel, Placebo. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.
Who might this study be for?
This study may concern people with depression; age range: From 18 Years to 65 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Naurex, Inc, an affiliate of Allergan plc, which appears to be another type of organization. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
